After the defense’s request to review exculpatory evidence was granted, the U.S District Court for the Northern District of California revealed that jury selection for the trial is to begin the week of July 28, 2020.
Today, a new generation of innovative biomedical startups continue to win billion-dollar valuations and massive infusions of venture capital as they promise to revolutionize medicine and disrupt massive healthcare markets. According to a new January paper authored by three Stanford researchers, many of these companies also publish little to no peer-reviewed research.
Last April, Facebook CEO Mark Zuckerberg sat, sweating, before a Congressional panel. Under scrutiny was how a British political consulting firm had gained access to the private data of more than 50 million Facebook users while, in the meantime, Russian operatives leveraged the platform as a tool to interfere in the election of a U.S. president.
Theranos was one of a handful of so-called “unicorns,” a Silicon Valley term for startup companies with a valuation of at least $1 billion.
On Feb. 23, Stanford filed a federal lawsuit against multiple Hewlett-Packard companies, seeking millions in damages for HP’s purported chemical contamination of “substantial portions” of 1601 S. California Avenue — land that Stanford owns — during a grading project sometime between 1970 and 1999. The named corporations in the original lawsuit are Hewlett-Packard Company and Hewlett Packard Enterprise (HPE) and Agilent Technologies.
For some Stanford startup founders, “anti-establishment” and privilege go hand in hand.